Creativ-Ceutical is now part of our team. Learn more here.
Log in or register to see all Alerts
Log in Register
Market Access Alerts >December 2021>Germany
New HTA Decisions in Germany
December 2021
Drug name
JEMPERLI® (dostarlimab)
Company
GlaxoSmithKline GmbH & Co. KG
Decision date
02/12/2021
About PHMR
Therapeutic area
Cancer
Therapeutic sub area
Endometrial cancers
G-BA decision date
02/12/2021
Orphan Drug?
No
Decision
No additional benefit
Indication
Adult patients with recurrent or advanced endometrial cancer, with mismatch repair deficiency/high microsatellite instability, that is progressive during or after previous treatment with a platinum based therapy. Appropriate comparator therapy: Therapy as prescribed by a doctor.
Decision Detail
Main studies: GARNET, ZotpEC and study registry 216960. Main driver of decision: The company presented subsequent data adjusted for potential confounders. In both of the indirect comparisons submitted, no sufficient structural equality of the treatment groups was achieved by the adjustment carried out. The confounder adjustment was insufficient for the benefit assessment.
Summary
In this addendum to commission, the decision of no added benefit made by IQWiG in September 2021 (original benefit assessment A21-84) was unchanged. The G-BA supported the decision made by IQWiG.


PHMR
Berkeley Works
Berkley Grove
London
NW1 8XY

+44 (0)20 3432 7450

info@phmr.com


 Understanding Payers

 Generating Evidence

 Developing Strategies

 Communicating Value

 Market Access Alerts

 Careers

 About us

 Contact us

 Cookie policy

 Privacy